Literature DB >> 28100772

De Novo Sphingolipid Biosynthesis Is Required for Adipocyte Survival and Metabolic Homeostasis.

Aikaterini Alexaki1, Benjamin A Clarke1, Oksana Gavrilova2, Yinyan Ma2, Hongling Zhu1, Xinran Ma1, Lingyan Xu1, Galina Tuymetova1, Bridget C Larman1, Maria L Allende1, Teresa M Dunn3, Richard L Proia4.   

Abstract

Sphingolipids are a diverse class of essential cellular lipids that function as structural membrane components and as signaling molecules. Cells acquire sphingolipids by both de novo biosynthesis and recycling of exogenous sphingolipids. The individual importance of these pathways for the generation of essential sphingolipids in differentiated cells is not well understood. To investigate the requirement for de novo sphingolipid biosynthesis in adipocytes, a cell type with highly regulated lipid metabolism, we generated mice with an adipocyte-specific deletion of Sptlc1 Sptlc1 is an obligate subunit of serine palmitoyltransferase, the enzyme responsible for the first and rate-limiting step of de novo sphingolipid biosynthesis. These mice, which initially developed adipose tissue, exhibited a striking age-dependent loss of adipose tissue accompanied by evidence of adipocyte death, increased macrophage infiltration, and tissue fibrosis. Adipocyte differentiation was not affected by the Sptlc1 deletion. The mice also had elevated fasting blood glucose, fatty liver, and insulin resistance. Collectively, these data indicate that de novo sphingolipid biosynthesis is required for adipocyte cell viability and normal metabolic function and that reduced de novo sphingolipid biosynthesis within adipocytes is associated with adipocyte death, adipose tissue remodeling, and metabolic dysfunction.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  adipocyte; inflammation; lipodystrophy; serine palmitoyltransferase; sphingolipid

Mesh:

Substances:

Year:  2017        PMID: 28100772      PMCID: PMC5339773          DOI: 10.1074/jbc.M116.756460

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Adipose tissue remodeling and obesity.

Authors:  Kai Sun; Christine M Kusminski; Philipp E Scherer
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

2.  Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.

Authors:  Saverio Cinti; Grant Mitchell; Giorgio Barbatelli; Incoronata Murano; Enzo Ceresi; Emanuela Faloia; Shupei Wang; Melanie Fortier; Andrew S Greenberg; Martin S Obin
Journal:  J Lipid Res       Date:  2005-09-08       Impact factor: 5.922

3.  Efficient in vivo manipulation of mouse genomic sequences at the zygote stage.

Authors:  M Lakso; J G Pichel; J R Gorman; B Sauer; Y Okamoto; E Lee; F W Alt; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Transcriptional control of adipose lipid handling by IRF4.

Authors:  Jun Eguchi; Xun Wang; Songtao Yu; Erin E Kershaw; Patricia C Chiu; Joanne Dushay; Jennifer L Estall; Ulf Klein; Eleftheria Maratos-Flier; Evan D Rosen
Journal:  Cell Metab       Date:  2011-03-02       Impact factor: 27.287

5.  Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk.

Authors:  Fahumiya Samad; Kelly D Hester; Guang Yang; Yusuf A Hannun; Jacek Bielawski
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

6.  Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1.

Authors:  Yutong Zhao; Satish K Kalari; Peter V Usatyuk; Irina Gorshkova; Donghong He; Tonya Watkins; David N Brindley; Chaode Sun; Robert Bittman; Joe G N Garcia; Evgeni V Berdyshev; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2007-03-22       Impact factor: 5.157

7.  Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice.

Authors:  Mohammad Reza Hojjati; Zhiqiang Li; Xian-Cheng Jiang
Journal:  Biochim Biophys Acta       Date:  2005-08-24

8.  Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.

Authors:  Sarah M Turpin; Hayley T Nicholls; Diana M Willmes; Arnaud Mourier; Susanne Brodesser; Claudia M Wunderlich; Jan Mauer; Elaine Xu; Philipp Hammerschmidt; Hella S Brönneke; Aleksandra Trifunovic; Giuseppe LoSasso; F Thomas Wunderlich; Jan-Wilhelm Kornfeld; Matthias Blüher; Martin Krönke; Jens C Brüning
Journal:  Cell Metab       Date:  2014-10-07       Impact factor: 27.287

9.  Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance.

Authors:  James Boon; Andrew J Hoy; Romana Stark; Russell D Brown; Ruth C Meex; Darren C Henstridge; Simon Schenk; Peter J Meikle; Jeffrey F Horowitz; Bronwyn A Kingwell; Clinton R Bruce; Matthew J Watt
Journal:  Diabetes       Date:  2012-11-08       Impact factor: 9.461

10.  Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.

Authors:  Jacob M Haus; Sangeeta R Kashyap; Takhar Kasumov; Renliang Zhang; Karen R Kelly; Ralph A Defronzo; John P Kirwan
Journal:  Diabetes       Date:  2008-11-13       Impact factor: 9.461

View more
  20 in total

Review 1.  Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-11-08       Impact factor: 4.810

Review 2.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

Review 3.  The role of dihydrosphingolipids in disease.

Authors:  Ruth R Magaye; Feby Savira; Yue Hua; Darren J Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H Wang
Journal:  Cell Mol Life Sci       Date:  2018-12-06       Impact factor: 9.261

Review 4.  Cholesterol - the devil you know; ceramide - the devil you don't.

Authors:  Trevor S Tippetts; William L Holland; Scott A Summers
Journal:  Trends Pharmacol Sci       Date:  2021-11-05       Impact factor: 14.819

Review 5.  Contribution of specific ceramides to obesity-associated metabolic diseases.

Authors:  Philipp Hammerschmidt; Jens C Brüning
Journal:  Cell Mol Life Sci       Date:  2022-07-05       Impact factor: 9.207

6.  You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.

Authors:  Joseph V Varre; William L Holland; Scott A Summers
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2022-02-23       Impact factor: 5.228

7.  The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes.

Authors:  Saifur R Khan; Haneesha Mohan; Ying Liu; Battsetseg Batchuluun; Himaben Gohil; Dana Al Rijjal; Yousef Manialawy; Brian J Cox; Erica P Gunderson; Michael B Wheeler
Journal:  Diabetologia       Date:  2019-01-15       Impact factor: 10.122

8.  Sptlc1 is essential for myeloid differentiation and hematopoietic homeostasis.

Authors:  Velayoudame Parthibane; Diwash Acharya; Sargur Madabushi Srideshikan; Jing Lin; Dru G Myerscough; Thiruvaimozhi Abimannan; Nagampalli Vijaykrishna; Daniel Blankenberg; Lavanya Bondada; Kimberly D Klarmann; Stephen D Fox; Thorkell Andresson; Lino Tessarollo; Usha Acharya; Jonathan R Keller; Jairaj K Acharya
Journal:  Blood Adv       Date:  2019-11-26

Review 9.  Ceramides in Metabolism: Key Lipotoxic Players.

Authors:  Bhagirath Chaurasia; Scott A Summers
Journal:  Annu Rev Physiol       Date:  2020-11-06       Impact factor: 19.318

Review 10.  Sphingolipids in metabolic disease: The good, the bad, and the unknown.

Authors:  Christopher D Green; Michael Maceyka; L Ashley Cowart; Sarah Spiegel
Journal:  Cell Metab       Date:  2021-07-06       Impact factor: 31.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.